A team from Washington State University and the Mayo Clinic has developed an electrochemical catheter hub that could dramatically reduce central line-associated bloodstream infections (CLABSIs), a major cause of hospital-related deaths. The device uses a low-voltage electric current to convert saline into hypochlorous acid—a disinfectant naturally produced by white blood cells—directly within the catheter hub. This continuous, low-dose antimicrobial activity targets bacteria like Acinetobacter baumannii, known for its antibiotic resistance and persistence on hospital surfaces.
The innovation hinges on a 3D-printed hub embedded with gold or titanium electrodes powered by a wearable micropotentiostat. Unlike traditional disinfection methods, this system generates the antimicrobial agent on demand, minimizing toxicity while maintaining efficacy. In lab tests, the gold-based electrodes proved most effective, consistently eliminating bacterial contamination without harming surrounding tissue.
Given the rise in CLABSI rates during the COVID-19 pandemic and the growing threat of antibiotic resistance, this technology offers a timely, non-antibiotic solution. The team is now preparing for animal trials and exploring broader applications. If successful, this could redefine infection control in hospitals and long-term care facilities.
Article from Washington State University: Electrochemical catheter hub could prevent bloodstream infections
Abstract from Biotechnology and Bioengineering: Electrochemical Catheter Hub Operated by a Wearable Micropotentiostat Prevents Acinetobacter baumannii Infection In Vitro
